Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019

Details for Mechanism ID: 18172
Country/Region: Vietnam
Year: 2018
Main Partner: FHI 360
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $4,058,871 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $388,536
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $97,134
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $200,000
Health Systems Strengthening (OHSS) $180,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $388,536
Sexual Prevention: Other Sexual Prevention (HVOP) $1,194,439
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $200,002
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,313,090
Treatment: Pediatric Treatment (PDTX) $97,134
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_SELF 2019 17,437
HTS_SELF 15-19, Female, Directly-Assisted 2019 148
HTS_SELF 15-19, Female, Unassisted 2019 286
HTS_SELF 15-19, Male, Directly-Assisted 2019 444
HTS_SELF 15-19, Male, Unassisted 2019 864
HTS_SELF 20-24, Female, Directly-Assisted 2019 491
HTS_SELF 20-24, Female, Unassisted 2019 950
HTS_SELF 20-24, Male, Directly-Assisted 2019 1,468
HTS_SELF 20-24, Male, Unassisted 2019 2,848
HTS_SELF 25-29, Female, Directly-Assisted 2019 517
HTS_SELF 25-29, Female, Unassisted 2019 1,008
HTS_SELF 25-29, Male, Directly-Assisted 2019 1,555
HTS_SELF 25-29, Male, Unassisted 2019 3,020
HTS_SELF 30-34, Female, Directly-Assisted 2019 283
HTS_SELF 30-34, Female, Unassisted 2019 545
HTS_SELF 30-34, Male, Directly-Assisted 2019 848
HTS_SELF 30-34, Male, Unassisted 2019 1,650
HTS_SELF 35-39, Female, Directly-Assisted 2019 16
HTS_SELF 35-39, Female, Unassisted 2019 32
HTS_SELF 35-39, Male, Directly-Assisted 2019 45
HTS_SELF 35-39, Male, Unassisted 2019 90
HTS_SELF 40-49, Female, Directly-Assisted 2019 17
HTS_SELF 40-49, Female, Unassisted 2019 26
HTS_SELF 40-49, Male, Directly-Assisted 2019 43
HTS_SELF 40-49, Male, Unassisted 2019 88
HTS_SELF 50+, Female, Directly-Assisted 2019 12
HTS_SELF 50+, Female, Unassisted 2019 23
HTS_SELF 50+, Male, Directly-Assisted 2019 37
HTS_SELF 50+, Male, Unassisted 2019 83
HTS_SELF Directly-Assisted 2019 5,921
HTS_SELF Unassisted 2019 11,516
HTS_TST 25-29, Female, Negative 2019 668
HTS_TST 25-29, Female, Negative 2019 202
HTS_TST 25-29, Female, Negative 2019 676
HTS_TST 25-29, Female, Negative 2019 4,061
HTS_TST 25-29, Male, Negative 2019 1,590
HTS_TST 25-29, Male, Negative 2019 480
HTS_TST 25-29, Male, Negative 2019 1,636
HTS_TST 25-29, Male, Negative 2019 9,651
HTS_TST 30-34, Female, Negative 2019 587
HTS_TST 30-34, Female, Negative 2019 177
HTS_TST 30-34, Female, Negative 2019 583
HTS_TST 30-34, Female, Negative 2019 3,556
HTS_TST 30-34, Male, Negative 2019 1,511
HTS_TST 30-34, Male, Negative 2019 456
HTS_TST 30-34, Male, Negative 2019 1,516
HTS_TST 30-34, Male, Negative 2019 9,147
HTS_TST 35-39, Female, Negative 2019 337
HTS_TST 35-39, Female, Negative 2019 101
HTS_TST 35-39, Female, Negative 2019 334
HTS_TST 35-39, Female, Negative 2019 2,034
HTS_TST 35-39, Male, Negative 2019 668
HTS_TST 35-39, Male, Negative 2019 202
HTS_TST 35-39, Male, Negative 2019 691
HTS_TST 35-39, Male, Negative 2019 4,061
HTS_TST 40-49, Female, Negative 2019 170
HTS_TST 40-49, Female, Negative 2019 51
HTS_TST 40-49, Female, Negative 2019 174
HTS_TST 40-49, Female, Negative 2019 1,018
HTS_TST 40-49, Male, Negative 2019 170
HTS_TST 40-49, Male, Negative 2019 51
HTS_TST 40-49, Male, Negative 2019 210
HTS_TST 40-49, Male, Negative 2019 1,018
HTS_TST By Key Population: FSW, Negative 2019 3,957
HTS_TST By Key Population: MSM, Negative 2019 9,374
HTS_TST By Key Population: People in prisons and other enclosed settings, Negative 2019 432
HTS_TST By Key Population: PWID, Negative 2019 13,515
HTS_TST By Key Population: TG, Negative 2019 140
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 73,082
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Female, Negative 2019 51
HTS_TST Service Delivery Point (Community) Index Mod: 15-19, Male, Negative 2019 76
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Female, Negative 2019 152
HTS_TST Service Delivery Point (Community) Index Mod: 20-24, Male, Negative 2019 480
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Female, Negative 2019 26
HTS_TST Service Delivery Point (Community) Index Mod: 50+, Male, Negative 2019 23
HTS_TST Service Delivery Point (Community) Other: 15-19, Female, Negative 2019 163
HTS_TST Service Delivery Point (Community) Other: 15-19, Male, Negative 2019 257
HTS_TST Service Delivery Point (Community) Other: 20-24, Female, Negative 2019 511
HTS_TST Service Delivery Point (Community) Other: 20-24, Male, Negative 2019 1,609
HTS_TST Service Delivery Point (Community) Other: 50+, Female, Negative 2019 84
HTS_TST Service Delivery Point (Community) Other: 50+, Male, Negative 2019 96
HTS_TST Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 170
HTS_TST Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 250
HTS_TST Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 506
HTS_TST Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,590
HTS_TST Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 82
HTS_TST Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 83
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 1,018
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 1,523
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 3,049
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 9,651
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 509
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 511
HTS_TST_POS 25-29, Female, Positive 2019 52
HTS_TST_POS 25-29, Female, Positive 2019 17
HTS_TST_POS 25-29, Female, Positive 2019 31
HTS_TST_POS 25-29, Female, Positive 2019 123
HTS_TST_POS 25-29, Male, Positive 2019 124
HTS_TST_POS 25-29, Male, Positive 2019 40
HTS_TST_POS 25-29, Male, Positive 2019 78
HTS_TST_POS 25-29, Male, Positive 2019 298
HTS_TST_POS 30-34, Female, Positive 2019 46
HTS_TST_POS 30-34, Female, Positive 2019 14
HTS_TST_POS 30-34, Female, Positive 2019 28
HTS_TST_POS 30-34, Female, Positive 2019 108
HTS_TST_POS 30-34, Male, Positive 2019 115
HTS_TST_POS 30-34, Male, Positive 2019 36
HTS_TST_POS 30-34, Male, Positive 2019 72
HTS_TST_POS 30-34, Male, Positive 2019 278
HTS_TST_POS 35-39, Female, Positive 2019 24
HTS_TST_POS 35-39, Female, Positive 2019 8
HTS_TST_POS 35-39, Female, Positive 2019 17
HTS_TST_POS 35-39, Female, Positive 2019 62
HTS_TST_POS 35-39, Male, Positive 2019 52
HTS_TST_POS 35-39, Male, Positive 2019 17
HTS_TST_POS 35-39, Male, Positive 2019 32
HTS_TST_POS 35-39, Male, Positive 2019 124
HTS_TST_POS 40-49, Female, Positive 2019 10
HTS_TST_POS 40-49, Female, Positive 2019 5
HTS_TST_POS 40-49, Female, Positive 2019 9
HTS_TST_POS 40-49, Female, Positive 2019 30
HTS_TST_POS 40-49, Male, Positive 2019 9
HTS_TST_POS 40-49, Male, Positive 2019 5
HTS_TST_POS 40-49, Male, Positive 2019 10
HTS_TST_POS 40-49, Male, Positive 2019 30
HTS_TST_POS By Key Population: FSW, Positive 2019 62
HTS_TST_POS By Key Population: MSM, Positive 2019 874
HTS_TST_POS By Key Population: People in prisons and other enclosed settings, Positive 2019 7
HTS_TST_POS By Key Population: PWID, Positive 2019 512
HTS_TST_POS By Key Population: TG, Positive 2019 7
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Female, Positive 2019 5
HTS_TST_POS Service Delivery Point (Community) Index Mod: 15-19, Male, Positive 2019 7
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Female, Positive 2019 13
HTS_TST_POS Service Delivery Point (Community) Index Mod: 20-24, Male, Positive 2019 40
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Female, Positive 2019 2
HTS_TST_POS Service Delivery Point (Community) Index Mod: 50+, Male, Positive 2019 1
HTS_TST_POS Service Delivery Point (Community) Other: 15-19, Female, Positive 2019 8
HTS_TST_POS Service Delivery Point (Community) Other: 15-19, Male, Positive 2019 12
HTS_TST_POS Service Delivery Point (Community) Other: 20-24, Female, Positive 2019 24
HTS_TST_POS Service Delivery Point (Community) Other: 20-24, Male, Positive 2019 77
HTS_TST_POS Service Delivery Point (Community) Other: 50+, Female, Positive 2019 3
HTS_TST_POS Service Delivery Point (Community) Other: 50+, Male, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 9
HTS_TST_POS Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 17
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 39
HTS_TST_POS Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 124
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 30
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 50
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 96
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 299
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 16
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 22
KP_PREV By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 137
KP_PREV By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 3,855
KP_PREV By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 9,433
KP_PREV By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) 2019 1,098
KP_PREV Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required 2019 14,523
PP_PREV 25-29, Female 2019 943
PP_PREV 25-29, Male 2019 2,828
PP_PREV 30-34, Female 2019 943
PP_PREV 30-34, Male 2019 2,828
PP_PREV 35-39, Female 2019 643
PP_PREV 35-39, Male 2019 1,929
PP_PREV 40-49, Female 2019 643
PP_PREV 40-49, Male 2019 1,929
PP_PREV Age/sex: 10-14 Female 2019 128
PP_PREV Age/sex: 10-14 Male 2019 387
PP_PREV Age/sex: 15-19 Female 2019 128
PP_PREV Age/sex: 15-19 Male 2019 387
PP_PREV Age/sex: 20-24 Female 2019 643
PP_PREV Age/sex: 20-24 Male 2019 1,929
PP_PREV Age/sex: 50+ Female 2019 216
PP_PREV Age/sex: 50+ Male 2019 629
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2019 17,133
PP_PREV Sum of Age/Sex disaggregates 2019 4,447
PrEP_NEW 25-29, Female 2019 14
PrEP_NEW 25-29, Male 2019 39
PrEP_NEW 30-34, Female 2019 6
PrEP_NEW 30-34, Male 2019 18
PrEP_NEW 35-39, Female 2019 1
PrEP_NEW 35-39, Male 2019 7
PrEP_NEW 40-49, Female 2019 1
PrEP_NEW 40-49, Male 2019 3
PrEP_NEW Female 15-19 2019 1
PrEP_NEW Female 20-24 2019 14
PrEP_NEW Male 15-19 2019 3
PrEP_NEW Male 20-24 2019 39
PrEP_NEW Male 50+ 2019 4
PrEP_NEW MSM 2019 135
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 150
PrEP_NEW Other Key Populations 2019 7
PrEP_NEW TG 2019 8
TB_PREV By Age/Sex (Numerator): <15, Female 2019 26
TB_PREV By Age/Sex (Numerator): <15, Male 2019 26
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 583
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 1,088
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 1,723
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 2,027
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 29
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 29
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 684
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 1,285
TX_CURR 25-29, Female, Positive 2019 2,897
TX_CURR 25-29, Male, Positive 2019 5,473
TX_CURR 30-34, Female, Positive 2019 2,575
TX_CURR 30-34, Male, Positive 2019 5,151
TX_CURR 35-39, Female, Positive 2019 1,288
TX_CURR 35-39, Male, Positive 2019 2,575
TX_CURR 40-49, Female, Positive 2019 643
TX_CURR 40-49, Male, Positive 2019 643
TX_CURR Age/Sex: <1-9 2019 100
TX_CURR Age/Sex: 10-14 Female 2019 50
TX_CURR Age/Sex: 10-14 Male 2019 41
TX_CURR Age/Sex: 15-19 Female 2019 643
TX_CURR Age/Sex: 15-19 Male 2019 966
TX_CURR Age/Sex: 20-24 Female 2019 2,897
TX_CURR Age/Sex: 20-24 Male 2019 5,795
TX_CURR Age/Sex: 50+ Female 2019 322
TX_CURR Age/Sex: 50+ Male 2019 319
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 32,378
TX_CURR Sum of age/sex disaggregates 2019 1,609
TX_NEW 25-29, Female, Positive 2019 478
TX_NEW 25-29, Male, Positive 2019 899
TX_NEW 30-34, Female, Positive 2019 424
TX_NEW 30-34, Male, Positive 2019 849
TX_NEW 35-39, Female, Positive 2019 212
TX_NEW 35-39, Male, Positive 2019 424
TX_NEW 40-49, Female, Positive 2019 104
TX_NEW 40-49, Male, Positive 2019 104
TX_NEW By Age/Sex: 1-9 2019 12
TX_NEW By Age/Sex: 10-14 Female 2019 4
TX_NEW By Age/Sex: 15-19 Female 2019 104
TX_NEW By Age/Sex: 15-19 Male 2019 161
TX_NEW By Age/Sex: 20-24 Female 2019 478
TX_NEW By Age/Sex: 20-24 Male 2019 955
TX_NEW By Age/Sex: 50+ Female 2019 55
TX_NEW By Age/Sex: 50+ Male 2019 53
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 5,316
TX_NEW Sum of Age/Sex disaggregates 2019 1,810
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 31,542
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Routine 2019 488
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 488
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 10,697
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 19,869
TX_PVLS_den Denominator: Indication: Routine 2019 31,542
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 10
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 794
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 1,472
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 2,280
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 2,534
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 12
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 882
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 4
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 1,636
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 29,142
TX_TB Number of ART patients who were started on TB treatment during the reporting period 2019 431
TX_TB Numerator: By Aggregated Age/Sex: <15, Female 2019 4
TX_TB Numerator: By Aggregated Age/Sex: <15, Male 2019 4
TX_TB Numerator: By Aggregated Age/Sex: 15+, Female 2019 144
TX_TB Numerator: By Aggregated Age/Sex: 15+, Male 2019 279
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 455
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 455
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 9,883
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 18,349